H.C. Wainwright Starts Inhibikase Therapeutics Inc (IKT) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts IKT Hot Sheet
Price: $1.54 --0%
Rating Summary:
6 Buy, 2 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 5 | Down: 13 | New: 4
Rating Summary:
6 Buy, 2 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 5 | Down: 13 | New: 4
Join SI Premium – FREE
H.C. Wainwright analyst Ed White initiates coverage on Inhibikase Therapeutics Inc (NASDAQ: IKT) with a Buy rating.
For an analyst ratings summary and ratings history on Inhibikase Therapeutics Inc click here. For more ratings news on Inhibikase Therapeutics Inc click here.
Shares of Inhibikase Therapeutics Inc closed at $0.58 yesterday.
You May Also Be Interested In
- Stephens Starts Dropbox (DBX) at Equal Weight, 'Show Us Growth'
- Morgan Stanley Starts Pony AI Inc (PONY) at Overweight
- H.C. Wainwright Starts Teva Pharma (TEVA) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
